Ovagen

What it is

The basic idea of the Khavinson school: short peptide fragments that are supposed to control the respective tissue are identified from organ extracts of young animals and then reproduced chemically. For the liver, in the 2006 patent, this is the sequence glutamic acid, aspartic acid, leucine, EDL for short, with the trade name Ovagen. The inventors are Khavinson, Grigoriev, Malinin and Ryzhak; the priority date is May 30, 2006.

In the group’s reviews, EDL is listed together with other short peptides and described there with two areas of responsibility: regulation of kidney cells and liver protection. This dual role is important for classification, because it shows that the advertised tissue specificity is not sharp here either.

Two confusions are common. First, with Livagen, the tetrapeptide KEDA, which is also sold as a liver peptide and has its own body of data. Second, with products for the ovaries or hormones: the name Ovagen suggests this, but no study on it exists.

How it is supposed to work

According to the school’s hypothesis, ultrashort peptides reach the cell nucleus, bind to DNA and histones and thus change the reading of genes. For EDL this pathway has been traced in cell culture: in aging kidney cell cultures, EDL and the sister peptide AED lowered the aging markers p16, p21 and p53 and increased SIRT-6 and cell division. A computational model assigns the binding of both peptides to the minor groove of AT-rich DNA segments.

A second paper by the same group separates the roles more clearly: in aging kidney cells, AED drove cell renewal, while the actual target of EDL was the gelatinase MMP-14, an enzyme of tissue remodeling. For a peptide sold as a liver bioregulator, this is an unusual core finding.

How the swallowed peptide is supposed to reach the liver or kidney has not been measured but modeled: a 2022 paper calculates how well ultrashort peptides, Ovagen among them, could bind to the transporters of the POT and LAT families. This is a plausibility calculation, not proof of uptake in humans.

What the studies show

The patent example with 34 hepatitis patients

The only use in humans is described in patent WO2007139430: 34 patients with chronic hepatitis aged 30 to 56 years received injections over ten days, a control group of 15 patients conventional treatment. 89 percent of those treated reported less fatigue, better appetite and greater capacity, 53 percent markedly less pain; bilirubin and ALT normalized. Randomization and blinding are not described, individual values for the control group are not given in the text, and the result was never published in a journal. There is no entry in ClinicalTrials.gov.

Acute kidney failure in rats (2015 and 2017)

Zamorskii and colleagues, with Khavinson as co-author, tested EDL in rats with cisplatin-induced kidney failure: urine output, urinary creatinine, filtration capacity and sodium reabsorption normalized, and protein excretion fell. In 2017 models with gentamicin and with a stop in blood flow followed, in which the peptide prevented the critical reduction of the antioxidant enzymes and supported the energy metabolism of the kidney cells.

Kidneys of old rats (2018)

In old rats, the kidney polypeptide complex and the peptides AED and EDL increased urine output 1.2- to 1.4-fold, EDL increased sodium excretion 1.6-fold. In the kidney the antioxidant enzymes rose, lipid oxidation fell, and tissue examination showed no signs of kidney damage.

Aging kidney cells in culture (2014)

In primary kidney cell cultures, AED and EDL lowered the aging markers p16, p21 and p53 and increased SIRT-6 and cell division. In the second paper, MMP-14 was the target of EDL, while the polypeptide complex and AED drove cell renewal. Both papers are cell experiments and say nothing about the effect of a swallowed capsule.

Where the data stop

There is no randomized, blinded or placebo-controlled study in humans, no peer-reviewed patient paper and no registry entry. The one patient use was by injection; whether the peptide reaches the liver or kidney at all as a capsule has not been measured, only estimated by computer.

In terms of content, there is a gap between sales and literature. The liver is advertised, the rat kidney is what appeared peer-reviewed; the liver data are in the inventors’ patent. The common concerns – fatty liver, elevated liver values after alcohol, liver fibrosis – have never been specifically studied, and the chromatin and marker findings also come from kidney cells, not liver cells.

Finally, the data are limited to one line of research: St. Petersburg and a group in Chernivtsi, with Khavinson as co-author. This does not speak against the findings, but it leaves independent replication as an open task – similar to Cartalax and Crystagen, whose human evidence also appears only in patent specifications.

Status, approval and legal

Ovagen is not an approved medicine in Germany or the EU. As a food supplement it would require authorization under the Novel Food Regulation (EU) 2015/2283, which does not exist. The peptide is patented as an agent for stimulating liver regeneration (RU 2297239 and WO2007139430, priority 30.05.2006). An approval as a medicine in Russia could not be verified; it is sold as a capsule product or research peptide by online retailers.

In sport, group S0 of the World Anti-Doping Agency applies: Ovagen is not named on the 2026 Prohibited List, but falls under it as a non-approved substance and is thus prohibited at all times.

Safety

There are no systematic safety data in humans. The toxicology comes from the patent specification: a single dose in 66 mice without observed reactions, 90 days of daily administration in 55 rats and six months in 88 guinea pigs, each without abnormal organ or blood findings. In addition there is the ten-day use in the 34 patients of the patent example, from which no side effects are reported – which means little with this form of reporting.

What is missing is pharmacokinetics in humans, information on interactions and any long-term observation. Elevated liver values, a fatty liver, hepatitis or kidney disease belong in medical workup and treatment; a peptide from the gray market does not replace a diagnosis, and with research-grade products content and purity are unverified.

Sources

• Khavinson et al., Patent WO2007139430 – H-Glu-Asp-Leu-OH for liver regeneration: organ culture, animal models, toxicology, patient example
• Zamorskii et al., Bull Exp Biol Med 2017 – nephroprotective effect of EDL in acute kidney injury
• Zamorskii et al., Bull Exp Biol Med 2015 – peptides in cisplatin-induced acute kidney failure
• Zamorskii et al., Adv Gerontol 2018 – peptides and kidney function in old rats (Russian)
• Khavinson et al., Adv Gerontol 2014 – AED and EDL slow aging in kidney cell cultures (Russian)
• Khavinson et al., Bull Exp Biol Med 2014 – signaling molecules in aging kidney cell cultures, MMP-14 as target of EDL
• Khavinson et al., Molecules 2021 – peptides and gene expression: EDL (Ovagen) as kidney and liver peptide (review)
• Khavinson et al., Int J Mol Sci 2022 – transport of ultrashort peptides via POT and LAT carriers (Ovagen listed)
• ClinicalTrials.gov – search for Ovagen without a registered study
• NADA – Prohibited List 2026, informational translation (group S0)